Coronary Artery Disease, Myocardial Infarction
Conditions
Keywords
irisin, myocardial infarction, coronary
Brief summary
The investigators aim to evaluate circulating irisin levels alterations in patients with acute myocardial infraction and in patients with coronary artery disease subjected to percutaneous coronary intervention.
Detailed description
Irisin is a newly discovered myokine induced in exercise. There is evidence that cardiac muscle produces more irisin than skeletal muscle in response to exercise. Furthermore, irisin has been associated with isoproterenol-induced myocardial infarction (MI) in rats while it has been reported to decrease after acute myocardial infarction in humans. The investigators aim 1) to investigate circulating irisin levels in patients at the time of acute myocardial infarction and after reprefusion \[primary percutaneous coronary intervention (PCI)\] 2) to compare irisin' s diagnostic and prognostic value and specificity value in myocardial infarction with known markers of cardiac injury such as creatine kinase-MB isoenzyme (CK-MB) and troponin 3) to evaluate irisin as an early necrosis biomarker 4) To evaluate irisin's sensitivity as a biomarker to detect minor myocardial necrosis after elective percutaneous coronary intervention
Interventions
PROCEDUREpercutaneous coronary intervention
a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
PROCEDUREcoronary angiography
is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
DEVICEStent, Medronic Resolute Integrity
A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
Sponsors
424 General Military Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with acute myocardial infraction (MI) or with coronary artery disease without myocardial infraction who need percutaneous coronary intervention
Exclusion criteria
* age \< 20 years old * diseases or medications that could affect cardiac muscle or skeletal muscle metabolism * musculoskeletal injury of surgery 6 months prior to recruitment * severe liver or kidney disease (creatinine clearance \< 60ml/min/1.73m2) or liver or kidney transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes from baseline in serum irisin measured by ELISA | baseline and 6 hours or 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| changes from baseline in troponin | baseline and 6 hours or 24 hours |
| changes from baseline in serum lactate dehydrogenase | baseline and 6 hours or 24 hours |
| changes from baseline in serum creatine kinase | baseline and 6 hours or 24 hours |
| changes from baseline in serum creatine kinase-MB isoenzyme | baseline and 6 hours or 24 hours |
| changes from baseline in serum follistatin | baseline and 6 hours or 24 hours |
| changes from baseline in serum follistatin-like protein 3 (FSTL-3) | baseline and 6 hours or 24 hours |
| changes from baseline in serum Activin A | baseline and 6 hours or 24 hours |
| changes from baseline in serum Activin B | baseline and 6 hours or 24 hours |
| changes from baseline in serum insulin growth factor 1 (IGF1) | baseline and 6 hours or 24 hours |
| changes from baseline in serum insulin growth factor binding protein 3 (IGFBP3) | baseline and 6 hours or 24 hours |
| changes from baseline in serum insulin growth factor binding protein 4 (IGFBP4) | baseline and 6 hours or 24 hours |
| changes from baseline in serum pico pregnancy-associated plasma protein A (PAPP-A) | baseline and 6 hours or 24 hours |
Countries
Greece
Outcome results
None listed